Intravenous Iron in HFpEF: What the FAIR-HFpEF Trial Could—and Could Not—Show
ABSTRACT:
Study at a glance
- Publication type: Multicentre, randomized, double-blind trial
- What it examined: FAIR-HFpEF compared intravenous ferric carboxymaltose with placebo in people with symptomatic HFpEF and iron deficiency.
- Key point: The trial stopped early because recruitment was slow, after 39 participants. At 24 weeks, the reported between-group difference in six-minute walking distance was 49 m (95% CI 5-93; P=.029).
Why it matters
Early stopping and the small sample substantially limit certainty. The result is a signal for further research, not a stand-alone treatment recommendation.
Source
Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J. 2024. PMID: 39185895. View the PubMed record.
This educational summary is based on the cited publication and is not medical advice. Clinical decisions should be made with an appropriately qualified healthcare professional.
